CHO Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1.43	3.58	-	0.06	3.57
Revenue Growth (YoY)	-60.03%	-	-	-98.32%	2486.96%
Cost of Revenue	0.37	1.87	-	0	0.21
Gross Profit	1.07	1.71	-	0.06	3.36
Selling, General & Admin	40.06	31.93	29.61	24.86	20.35
Research & Development	286.85	219.08	239.39	326.1	193.51
Operating Expenses	326.91	251	269	350.96	213.85
Operating Income	-325.84	-249.29	-269	-350.9	-210.49
Interest Expense	-0.41	-0.68	-0.08	-0.3	-0.58
Interest & Investment Income	36.26	37.68	16.24	7.05	5.46
Currency Exchange Gain (Loss)	-	0.07	-0.53	-0.13	0.22
Other Non Operating Income (Expenses)	-0.02	-	0.01	5.88	5.46
EBT Excluding Unusual Items	-290.01	-212.23	-253.36	-338.39	-199.93
Asset Writedown	-	-	-52.73	-	-6
Pretax Income	-290.01	-212.23	-306.09	-338.39	-205.93
Net Income	-290.01	-212.23	-306.09	-338.39	-205.93
Net Income to Common	-290.01	-212.23	-306.09	-338.39	-205.93
Shares Outstanding (Basic)	213	214	191	184	184
Shares Outstanding (Diluted)	213	214	191	184	184
Shares Change (YoY)	-0.36%	11.86%	4.00%	0.04%	0.12%
EPS (Basic)	-1.36	-0.99	-1.60	-1.84	-1.12
EPS (Diluted)	-1.36	-0.99	-1.60	-1.84	-1.12
Free Cash Flow	-288.87	-222.87	-293.13	-258.9	-196.11
Free Cash Flow Per Share	-1.35	-1.04	-1.53	-1.41	-1.07
Gross Margin	74.49%	47.77%	-	98.33%	94.09%
Operating Margin	-22770.16%	-6963.49%	-	-584833.33%	-5896.11%
Profit Margin	-20265.97%	-5928.10%	-	-563988.33%	-5768.21%
Free Cash Flow Margin	-20186.58%	-6225.53%	-	-431501.67%	-5493.25%
EBITDA	-299.15	-237.71	-250.3	-324.67	-184.88
D&A For EBITDA	26.69	11.59	18.7	26.23	25.61
EBIT	-325.84	-249.29	-269	-350.9	-210.49

Source: S&P Global Market Intelligence. Standard template. Financial Sources.